[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Tularemia Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 40 pages | ID: TCC7A1C3CB8EEN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Tularemia Drug pipeline report- 2020 is an annual R&D review of Tularemia pipeline candidates. The report presents the current status of all major Tularemia therapeutic compounds. Detailed insights into Tularemia pipeline development, current status, companies, drug profiles and Tularemia preclinical and clinical trials are included.

2020 Tularemia Pipeline Market Insights
Tularemia disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Tularemia therapies, pipeline by phase and others are included.

Tularemia pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Tularemia Therapeutic Drug candidates
Both active and inactive Tularemia pipeline drug candidates are included in the report

Tularemia Clinical Trials and preclinical Studies
Tularemia In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Tularemia pipeline market developments
Tularemia Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Tularemia pipeline companies in active development
The report analyzes Tularemia pipeline of the below companies-

Appili Therapeutics Inc, Aradigm Corp, DynPort Vaccine Company LLC, Tetraphase Pharmaceuticals Inc

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
4 Companies investing in Tularemia pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Tularemia pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. TULAREMIA PIPELINE MARKET INSIGHTS, 2020

1.1 Tularemia Disease Overview
1.2 Tularemia Drug Pipeline Snapshot, 2020
  1.2.1 Tularemia Pipeline Drugs by Phase
  1.2.2 Tularemia Pipeline Drugs by Company
  1.2.3 Tularemia Pipeline Drugs by Mechanism of Action
  1.2.4 Tularemia Pipeline Drugs by Route of Administration

2. TULAREMIA COMPANY WISE PIPELINE DETAILS

Appili Therapeutics Inc Tularemia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Aradigm Corp Tularemia Pipeline Drugs
  Company Profile
  Drug Candidate Details
DynPort Vaccine Company LLC Tularemia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Tetraphase Pharmaceuticals Inc Tularemia Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. TULAREMIA DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. TULAREMIA PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications